Search clinical trials for: Poorly differentiated neuroendocrine carcinomas

Total 4852 results

Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Study of Kidney Tumors in Younger Patients

Renal Cell Carcinoma | Wilms Tumor | Clear Cell Sarcoma of the Kidney | Papillary Renal Cell Carcinoma | Kidney Medullary Carcinoma | Diffuse Hyperplastic Perilobar Nephroblastomatosis | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Renal Cell Carcinoma Associated With Xp11.2 Translocations... and other conditions

United States, Canada, Puerto Rico, Australia, New Zealand, Israel, Switzerland
Pfizer

Completed

The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Refractory Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Differentiated Thyroid Gland Carcinoma | Thyroid... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

HIV Infection | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Advanced... and other conditions

United States
M.D. Anderson Cancer Center

Suspended

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

Small Cell Lung Cancer | Hodgkin's Lymphoma | Cervical Carcinoma | Peritoneal Mesothelioma | Pleural Mesothelioma | Neuroendocrine Carcinomas | Microsatellite High Cancers | Extrapulmonary High Grade

United States
Amr Mohamed MD
Novatek Pharmaceuticals

Active, not recruiting

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Neuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

Sinonasal Undifferentiated Carcinoma | Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma | Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8 | Stage III Nasal Cavity and Paranasal Sinus Cancer... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Active, not recruiting

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Malignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditions

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; AstraZeneca

Active, not recruiting

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Prostate Carcinoma | Prostate Cancer Aggressiveness

United States
M.D. Anderson Cancer Center

Active, not recruiting

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Cervical Cancer | Cervix Cancer | Carcinomas

United States
AC Camargo Cancer Center
H. Lee Moffitt Cancer Center and Research Institute

Completed

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET)

Neuroendocrine Tumors | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive Tumor

United States, Brazil
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

Neuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVA Thyroid Gland...

United States
RayzeBio, Inc.

Active, not recruiting

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1)

Neuroendocrine Tumors | Carcinoid Tumor | Gastroenteropancreatic Neuroendocrine Tumor | Carcinoid | GEP-NET | Gastroenteropancreatic Neuroendocrine Tumor Disease | Pancreatic NET

Canada, Spain, United States, Netherlands, Belgium, France, Brazil
Foghorn Therapeutics Inc.

Terminated

FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Advanced Synovial Sarcoma

United States, Spain, France, Italy
IRCCS San Raffaele

Active, not recruiting

Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs (FARINET)

Neuroendocrine Tumors | GEP-NET

Italy
National Cancer Institute (NCI)

Active, not recruiting

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Recurrent Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage III Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Active, not recruiting

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Cancer

United States
Saint Petersburg State University, Russia

Withdrawn

Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage

Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Thyroid Gland Medullary Carcinoma | Differentiated Thyroid Gland Carcinoma | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma

United States
Memorial Sloan Kettering Cancer Center

Completed

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Thyroid Cancer, Papillary | Thyroid Cancer, Follicular | Thyroid Carcinoma | Thyroid Cancer | Thyroid Cancer (Follicular Cell) | BRAF V600E Mutation Positive

United States
Zhejiang University

Completed

Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma

Colorectal Neuroendocrine Carcinomas (CRNEC); Genomic Landscape; Genetic Landscape; Prognosis; CCL5; PAX5
Haramaya Unversity

Completed

Poorly Differentiated Adenocarcinoma of the Jejunum in a Patient With Peutz-Jeghers Syndrome: A Case Report

Peutz-Jeghers Syndrome

Ethiopia
Assistance Publique - Hôpitaux de Paris
Ipsen

Completed

Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors (TNE-bien-DIF)

Neuroendocrine Tumors

France
Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc.

Completed

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Thyroid Cancer | Differentiated Thyroid Cancer | Anaplastic Thyroid Cancer

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Poorly Differentiated Thyroid Gland Carcinoma | Recurrent Differentiated Thyroid Gland Carcinoma | Columnar Cell Variant Thyroid Gland Papillary Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Metastatic Thyroid Gland Follicular Carcinoma | Metastatic Thyroid Gland Papillary... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Thyroid Cancer, Follicular | Thyroid Cancer | Papillary Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid Cancer | Hurthle Cell Tumor | Hurthle Cell Thyroid Neoplasia

United States
The Christie NHS Foundation Trust
Pancreatic Cancer UK

Completed

Pancreatic Cancer Dietary Assessment Study (PanDA)

Pancreas Adenocarcinoma | Pancreatic Neoplasm | Malignant Neoplasm of Pancreas | Well-Differentiated Neuroendocrine Carcinoma

United Kingdom
M.D. Anderson Cancer Center

Active, not recruiting

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Neuroendocrine Carcinoma | Stage IIIC Lung Cancer AJCC v8 | Lung Small Cell Carcinoma

United States
NCIC Clinical Trials Group

Completed

Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor

Head and Neck Cancer

Canada
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)

United States
junya mita

Completed

Poorly Differentiated Adenocarcinoma With Signet Ring Cells of the Gallbladder Producing a High Level of Alpha-fetoprotein: a Case Report

Gallbladder Cancer

Japan
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Carcinoma AJCC... and other conditions

United States
Novartis Pharmaceuticals

Completed

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Soft Tissue Sarcoma | Small Cell Lung Cancer | Gastric Adenocarcinoma | Diffuse Large B Cell Lymphoma | Esophageal Adenocarcinoma | Ovarian Adenocarcinoma | Castration Resistant Prostate Adenocarcinoma | Advanced Well-differentiated Neuroendocrine Tumors

United States
AC Camargo Cancer Center

Withdrawn

Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors (MIBNET)

Neuroendocrine Tumors

Brazil
Johannes Gutenberg University Mainz
Merck KGaA, Darmstadt, Germany

Completed

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy (AveNEC)

Cancer

Germany
Thomas Jefferson University

Active, not recruiting

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Differentiated Thyroid Cancer (DTC) | Poorly Differentiated Thyroid Cancer

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Active, not recruiting

Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs (MetNET1)

Well Differentiated Pancreatic Endocrine Tumor

Italy
Novartis Pharmaceuticals

Completed

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Melanoma | Triple Negative Breast Cancer | Endometrial Carcinoma | Pancreatic Carcinoma

United States, Germany, Italy, Japan, Belgium, Switzerland, Korea, Republic of, Hong Kong, Finland, France, Spain
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Thyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid Cancer

United States
The Netherlands Cancer Institute

Active, not recruiting

Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

Neuroendocrine Carcinomas

Netherlands
Istituto Scientifico Romagnolo per lo Studio e...

Unknown

CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas (SENECA)

Neuroendocrine Carcinoma

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Meningioma | Neuroendocrine Neoplasm | Multiple Endocrine Neoplasia Type 1 | Von Hippel-Lindau Syndrome | Metastatic Well Differentiated Neuroendocrine Neoplasm | Somatostatin Positive Neoplastic Cells Present

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Pancreatic Cancer | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinomas of Pancreas | Islet Cell Carcinoma

United States
Lei Li

Unknown

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Chemotherapy | Recurrent Cervical Carcinoma | Adverse Drug Event | Cervical Neuroendocrine Carcinoma | Objective Response Rate | Advanced Cervical Carcinoma | Anti-pd-1 Antibody

China
National Cancer Institute, Naples

Completed

Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas (TENEC)

Neuroendocrine Carcinomas

Italy
European Organisation for Research and Treatment...

Completed

Nintedanib(BIBF1120) in Thyroid Cancer

Differentiated Thyroid Cancer (DTC) | Medullary Thyroid Cancer (MTC)

France, Belgium, Denmark, Italy, Netherlands, Germany, Poland, Spain, United Kingdom
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVC Differentiated Thyroid Gland Carcinoma... and other conditions

United States, Taiwan, Australia, Singapore, China
European Organisation for Research and Treatment...
Ipsen

Withdrawn

Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome (TELEFIRST)

Small Intestinal NET | Carcinoid Heart Disease

Search clinical trials for: Poorly differentiated neuroendocrine carcinomas

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations